Raymond James upgraded Dyne Therapeutics (DYN) to Strong Buy from Outperform with a price target of $35, up from $31. The firm has increased conviction in Dyne’s DYNE-251 registrational cohort readout in late 2025. Raymond James expects a “differentiated profile” for DYN-251 versus Exondys 51 and sees a a path to accelerated approval. Dyne’s market opportunity for DYNE-251 in exon 51 Duchenne muscular dystrophy is underappreciated, contends the firm.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN: